{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc:iclusig:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahc%3Aiclusig%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001638,
    "timestamp_received": "2026-11-09T16:13:11.071703Z",
    "timestamp_returned": "2026-11-09T16:13:11.073341Z",
    "trace_id": "f56b371b-b761-4a3e-82ca-942331d46a12"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hc:iclusig:0",
      "type": "Indication",
      "description": "ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML that is T315I mutation positive or where there is prior TKI resistance or intolerance",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-30:0",
          "type": "Contribution",
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hc:iclusig",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Iclusig (ponatinib) [product monograph]. HC.",
          "title": null,
          "aliases": [],
          "description": "Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.",
          "urls": [
            "https://pdf.hres.ca/dpd_pm/00078669.PDF",
            "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hc",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Canada",
                "description": "Regulatory agency that approves drugs for sale and use in Canada."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Takeda Pharmaceuticals U.S.A., Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Iclusig",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "ponatinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2015-03-31",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2025-02-24",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "Health Canada approved ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}